Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Using antibiotics responsibly: right drug, right time, right dose, right duration.

Everyone prescribing antibiotics should consider both their clinical and public health responsibilities. The objective should be to provide optimal patient care while at the same time seeking to minimize selective pressure that may result in the emergence and spread of antibiotic resistance. To this end, in 2008 the European Centre for Disease Control initiated the annual European Antibiotic Aw...

متن کامل

Warfarin treatment and thrombolysis in acute stroke: are the procrastinators right?

Neurology 2012;79:17–18 IV thrombolysis is the only approved therapy for acute ischemic stroke. Clinical benefit for approximately 1 in 7 treated patients results when administered within 4.5 hours of stroke onset.1,2 The widespread use of IV thrombolysis is, however, hindered by symptomatic intracranial hemorrhage (sICH), which affects 2%– 8% of patients (depending on the definition of sICH em...

متن کامل

Choose the right treatment for the right patients

Age-relatedmacular degeneration (AMD) is one of themajor causes of adult visual loss. During the past decade, the use of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular eye disease has significantly changed the standard of care in retinal medicine and ophthalmology. Intravitreal injection of anti-VEGF drugs has since been widely employed clinically to...

متن کامل

Gestational diabetes mellitus—right person, right treatment, right time?

BACKGROUND Personalised treatment that is uniquely tailored to an individual's phenotype has become a key goal of clinical and pharmaceutical development across many, particularly chronic, diseases. For type 2 diabetes, the importance of the underlying clinical heterogeneity of the condition is emphasised and a range of treatments are now available, with personalised approaches being developed....

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: PLOS ONE

سال: 2020

ISSN: 1932-6203

DOI: 10.1371/journal.pone.0233316